Phase II study showed ocrelizumab maintained significant reduction in disease activity for MS patients
20 October 2011 | By Roche
Phase III trials underway to investigate ocrelizumab in two forms of MS...
List view / Grid view
20 October 2011 | By Roche
Phase III trials underway to investigate ocrelizumab in two forms of MS...
17 October 2011 | By Roche
Acquisition aims to expand future treatment options for hepatitis C patients...
17 October 2011 | By Roche
Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin...
10 October 2011 | By Roche
Monoclonal antibody gantenerumab removes amyloid plaques from the brain...
25 September 2011 | By Roche
Phase II study TDM4450g results announced...
19 September 2011 | By Roche
Data show greater understanding of disease pathways and personalising treatments...
8 September 2011 | By Roche
Roche recognized as the most sustainable healthcare company globally in the DJSI...
6 September 2011 | By Evotec AG
Evotec's MAO-B inhibitor in patients with Alzheimer's disease (AD) to be developed...
In this Genomics / Sequencing supplement: NGS powers up drug discovery and healthcare; Impact of novel sequencing technology on transcriptome analysis; Making sense of nonesense (and missense): Bringing the results of recent genetic studies into the drug discovery laboratory...
17 August 2011 | By Roche
First and only personalized medicine shown to help people with BRAF V600E mutation-positive metastatic melanoma...
4 August 2011 | By Roche
Lebrikizumab has potential to be the first personalized treatment for asthma...
3 August 2011 | By Roche
The European Commission has approved the use of RoACTEMRA (tocilizumab)...
25 July 2011 | By Roche
Roche has been awarded an exclusive contract by the National Health Laboratory Services (NHLS)...
20 July 2011 | By Merck
Merck has signed a new non-exclusive agreement with Roche...
19 July 2011 | By Roche
Roche has signed an agreement to acquire 100% of mtm laboratories AG (mtm)...